Related Articles
Cariprazine: New FDA Indication for MDD Augmentation
On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in…
Lumateperone: Newest FDA Approved Medication for Bipolar Depression
Dec 20, 2021. We know that Lumateperone received its first FDA approval for the management of adult schizophrenia in 2019, but FDA has just approved…
Understanding Hoover Test: to Differentiate Functional vs. Organic Limb Weakness
Motor Functional Neurological Disorders (FND) present a unique clinical challenge, often characterized by limb weakness or abnormal movements that are incongruent with known neurological diseases.…
Brexpiprazole + Sertraline: Could this be the next FDA-approved treatment for PTSD?
Post-Traumatic Stress Disorder (PTSD) remains a complex and challenging condition to treat, often requiring a combination of psychotherapy and pharmacological interventions. While sertraline has long…
Low Dose Naltrexone for MDD Augmentation: What Clinicians Should Know
Major depressive disorder (MDD) remains one of the most challenging psychiatric conditions to treat, especially in cases that are treatment-resistant. In recent years, low dose…